Skip to main content

Table 1 Demographic and clinical features of training set and validation set in the present study

From: Different expression pattern of human cytomegalovirus-encoded microRNAs in circulation from virus latency to reactivation

Variable

Training set

Validation set

Viremia (n = 23)

Control (n = 24)

P values

Viremia (n = 36)

Control (n = 36)

P values

Age, yearsa

44.1 ± 4.0

51.9 ± 3.6

0.15

52.8 ± 3.3

49.7 ± 3.2

0.50

Sex, n

  

0.19§

  

0.48§

 Male

9 (39.1%)

14 (58.3%)

 

19 (52.8%)

16 (44.4%)

 

 Female

14 (60.9%)

10 (41.7%)

 

17 (47.2%)

20 (55.6%)

 

HCMV DNA Levelb

1920 (1100, 3680)

 

1995 (795.5, 9995)

 

Anti-HCMV IgG (IU/mL)a

1.59 ± 0.16

1.74 ± 0.19

0.57

1.94 ± 0.16

1.63 ± 0.15

0.17

Anti-HCMV IgM, n

 Positive

0 (0%)

0 (0%)

 

0 (0%)

0 (0%)

 

 Negative

23 (100%)

24 (100%)

 

36 (100%)

36 (100%)

 

HCV, n

 Positive

0 (0%)

0 (0%)

 

0 (0%)

0 (0%)

 

 Negative

23 (100%)

24 (100%)

 

36 (100%)

36 (100%)

 

EB, n

  

0.19§

  

0.47§

 Positive

11 (47.8%)

16 (66.7%)

 

13 (36.1%)

16 (44.4%)

 

 Negative

12 (52.2%)

8 (33.3%)

 

23 (63.9%)

20 (55.6%)

 

HIV, n

 Positive

0 (0%)

0 (0%)

 

0 (0%)

0 (0%)

 

 Negative

23 (100%)

24 (100%)

 

36 (100%)

36 (100%)

 

Leukemia, n

  

0.61§

  

1§

 Yes

7 (30.4%)

9 (37.5%)

 

13 (36.1%)

13 (36.1%)

 

 No

16 (69.6%)

15 (62.5%)

 

23 (63.9%)

23 (63.9%)

 

Autoimmune diseases, n

  

0.81§

  

0.44§

 Yes

6 (26.1%)

7 (29.2%)

 

9 (25%)

12 (33.3%)

 

 No

17 (73.9%)

17 (70.8%)

 

27 (75%)

24 (66.7%)

 
  1. Student t test
  2. §Two-sided χ2 test
  3. aAge data and anti-HCMV IgG are presented as the mean ± SD
  4. bHCMV DNA level are presented as median (25% Percentile, 75% Percentile)